Intellectual Property India Publishes Patent Application for 'Bifunctional Compounds Containing 2,5-Substituted Pyrimidine Derivatives For Degrading Cyclin-Dependent Kinase 2 Via Ubiquitin Proteasome Pathway' Filed by Nikang Therapeutics, Inc.

MUMBAI, India, June 13 -- Intellectual Property India has published a patent application (202517049136 A) filed by Nikang Therapeutics, Inc., Wilmington, U.S.A., on May 21, for 'bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway.'

Inventor(s) include Yu, Zhiyong; and Lou, Yan.

The application for the patent was published on June 13, under issue no. 24/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated b...